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in rat gastrointestinal tracts
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Abstract
Background: Ginsenosides such as Rb1, Rg3 and Rh2 are major bioactive components of Panax ginseng. This in vivo 
study investigates the metabolic pathways of ginsenosides Rb1, Rg3 and Rh2 orally administered to rats.
Methods: High performance liquid chromatography-mass spectrometry (LC-MS) and tandem mass spectrometry (MS-
MS) techniques, particularly liquid chromatography electrospray ionization mass spectrometry (LC-ESI-MS), were used 
to identify the metabolites.
Results: Six metabolites of Rb1, six metabolites of Rg3 and three metabolites of Rh2 were detected in the feces samples 
of the rats. Rh2 was a metabolite of Rb1 and Rg3, whereas Rg3 was a metabolite of Rb1. Some metabolites such as 
protopanaxadiol and monooxygenated protopanaxadiol are metabolites of all three ginsenosides.
Conclusion: Oxygenation and deglycosylation are two major metabolic pathways of the ginsenosides in rat 
gastrointestinal tracts.
Background
Panax ginseng (Renshen) is used in Chinese medicines to
treat various conditions such as debility, ageing, stress,
diabetes, insomnia and sexual inadequacy [1-3]. The
major bioactive components of P. ginseng are O-glyco-
sides of the triterpen dammarane saponins known as gin-
senosides [4,5] which exhibit properties such as anti-
inflammation and anti-tumor [6-8]. Over 80 ginsenosides
have been isolated from P. ginseng [9]. Rb1, Rg3 and Rh2
are three major ginsenosides with various bioactivities.
Rb1, which is the most abundant (0.22-0.62%) among all
ginsenosides [5], protects against free radical damage,
maintains normal cholesterol and blood pressure [10]
and inhibits the induction phase of long-term potentia-
tion by high frequency stimulation in the dentate gyrus of
the brain [11]. Rb1 also rescues hippocampal neurons
from lethal ischemic damage [12] and delays neuronal
death from transient forebrain ischemia in vitro [13]. Rg3
is used as the major active component in an anti-tumor
and anti-cancer drug in China [14]. The cytotoxicity of
ginsenoside Rg3 against tumor cells increases when Rg3 is
metabolized into Rh2 or protopanaxadiol [15]. The meta-
bolic transformation of Rg3  into protopanaxadiol also
increases the activity against Helicobacter pylori.
Recently, in vitro biotransformation of ginsenosides was
reported. The metabolites were identified by high-resolu-
tion tandem mass spectrometry. Degradation and bio-
conversion routes of the different ginsenosides at acidic
(gastric) conditions and in the presence of intestinal
microbiota were elaborated [16].
High performance liquid chromatography (HPLC) is a
powerful chemical analysis technology that allows com-
plex mixtures to be transformed into separated compo-
nents. Mass spectrometry (MS) has progressed extremely
rapidly during the last decade; especially in production,
separation and ejection of ions, data acquisition and data
reduction. Compared to other detectors, the advantages
of the mass spectrometer are that in many cases it can
provide absolute identification, not only structural infor-
mation from the molecule under investigation but the
molecular weight of the analyte.
Due to the specificity and sensitivity of LC-MS, espe-
cially in combination with MS-MS, it is powerful in iden-
tification of drug metabolites. Common
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biotransformation,  e.g., oxidative reactions (hydroxyla-
tion), conjugation reactions to produces sulphates,
glucuronides, glutathiones or other conjugates, hydroly-
sis of esters and amides, and reduction reactions, can be
evaluated from just the knowledge of the molecular mass
of the metabolites. Combination of the molecular-mass
and possible biotransformation products, predicted by
computer-aided molecular modeling approaches, enables
the confirmation of metabolic pathways. Further confir-
mation and/or structure elucidation of metabolites is
possible using MS-MS methods [17]. The identification
of the metabolites of antihistamine compounds is feasible
by using thermospray LC-MS and LC-MS-MS [18,19].
The present study aims to investigate the biotransforma-
tion of ginsenosides Rb1, Rg3 and Rh2 orally administered
to rats by using LC-MS and MS-MS.
Methods
Chemicals
Ginsenosides Rb1, Rg3 and Rh2 (purity >99%) were pro-
vided by the Chinese Medicine Laboratory, Changchun
Institute of Applied Chemistry, Chinese Academy of Sci-
ences, China. HPLC-grade methanol was purchased from
Acros Organics (USA). A Mili-Q Ultra-pure water system
(Millipore, USA) was used to provide water for all the
experiments. Other chemicals (analytical grade) were
purchased from Sigma (USA).
Administration of ginsenosides
Water soluble Rb1, Rg3 and Rh2 were administered to
three groups (n = 3 in each group) of male Sprague Daw-
ley rats (body weight 200-220 g; age 6-7 weeks) respec-
tively at a dose of 100 mg/kg body weight with 2 ml
dosing solution. The protocols of the animal study were
fully complied with the University policy on the care and
use of animals and with related codes of practice. The
animal experiments were conducted with the licenses
granted by Hong Kong Hygiene and Health Department.
Rat feces samples were collected at such intervals: 0 to
120 hours for Rb1 (half-life 16.7 hours), 0 to 24 hours for
Rg3 (half-life 18.5 minutes) and 0 to 48 hours for Rh2
(half-life 16 minutes)[20-22].
Feces sample preparation
Each feces sample of each rat was suspended in 150 ml of
water and then extracted with n-butanol (100 ml × 3).
The extract was dried and the residue was dissolved in 1
ml of methanol. After centrifugation at 12000 rpm for 20
minutes (Eppendorf Centrifuge 5415R, Hamburg, Ger-
many), 2 μl of the supernatant was analyzed with LC-Ms
and LC-MS-MS for the identification of the ginsenosides
and their metabolites. The blank feces (baseline) were
collected from the same Sprague Dawley rat prior to the
administration of ginsenosides, prepared and analyzed
with the same method as the experimental groups.
LC-ESI-MS analysis
HPLC separation was performed with a LC system cou-
pled with an auto-sampler and a micro mode pump
(HP1100, Agilent Technologies, USA). A reversed-phase
column (Waters, Xterra MS-C8, 2.1 × 100 mm, 3.5 μm)
was used to separate the ginsenosides and their metabo-
lites. The auto-sampler was set at 10°C. Mobile phase
consisted of two eluents: water (A) and methanol (B).
Gradient elution was 40% B in 0-4 minutes, 40-90% B in
4-5 minutes, 90% B in 5-35 minutes, 90-40% B in 35-36
minutes and 40% B in 36-42 minutes at a flow rate of 100
μl/min. Effluent from the LC column was diverted to
waste for the first 12 minutes following the injection, and
then diverted to the MS ion source.
MS experiments were performed on a quadruple-time
of flight (Q-TOF) tandem mass spectrometer API Q-
STAR Pulsar I (Applied Biosystems, USA). Negative or
positive ion mode in electrospray ionization (ESI) was
used to analyze ginsenosides and their metabolites in rat
feces samples. The following parameters of the turbo-
ionspray for positive ion mode were used: ionspray volt-
age 5500 V, declustering potential 1 (DP1) 90 V, focusing
potential (FP) 265 V and declustering potential 2 (DP2)
10 V, collision energy (CE) 55 eV for MS-MS analysis. For
negative ion mode, the parameters were: ionspray voltage
-4200 V, declustering potential 1 (DP1) -90 V, focusing
potential (FP) -265 V and declustering potential 2 (DP2)
10 V, collision energy (CE) -60 eV for MS-MS analysis.
For both positive and negative ion mode, the ion source
gas 1 (GS1), gas 2 (GS2), curtain gas (CUR) and collision
gas (CAD) were 20, 15, 25 and 3, respectively. The tem-
perature of GS2 was set at 400°C.
Results and Discussion
Metabolites of Rb1 in rat feces
The parent Rb1 and direct oxygenated metabolites of Rb1
were not detected in the feces samples. These results sug-
gested that Rb1 might have largely metabolized in the gas-
trointestinal tracts in rats. Six metabolites were detected
in rat feces samples collected 0-120 hours after Rb1 was
orally administered (Figure 1). The metabolites were
detected from the LC-MS analyses and confirmed by the
results from the LC-MS-MS experiments in positive ESI
mode [18]. A total of four deglycosylated metabolites
were identified, namely Rd, Rg3, Rh2 and protopanaxadiol
(Figure 2). Analysis of [M + Na]+ ions (Figure 3) indicated
that the metabolites shared similar MS-MS fragmenta-
tion pattern with the parent Rb1. The fragmentation pat-
terns of the metabolites, produced from the [M + Na]+
ions at m/z 969, m/z 807, and m/z 645 respectively, wereQian and Cai Chinese Medicine 2010, 5:19
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Figure 1 Deglycosylated and oxygenated metabolic pathways of Rb1 orally administered to rats.
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Figure 2 MS spectra of Rb1 orally administered to rats. (A) Rd and its deglycosylated metabolites, m/z 969; (B) Rg3, m/z 807; (C) Rh2, m/z 645; (D) 
protopanaxadiol, m/z 483.
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Figure 3 LC-MS-MS spectra of ginsenosides. (A) Rb1 and its deglycosylated metabolites; (B) Rd; (C) Rg3; (D) Rh2.
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Figure 4 Metabolic pathways of Rg3 orally administered to rats.
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compared with that of Rb1. The deglycosylated metabo-
lites of Rb1 showed the same fragment patterns as Rb1, i.e.
the glucose moiety and water were lost from the molecu-
lar ion and the corresponding sodium-adduct daughter
ions at m/z 789 and m/z 203 for Rd, m/z 627 and m/z 365
for Rg3 and m/z 465 and m/z 203 for Rh2 were produced.
The deglycosylated metabolites were also confirmed by
the LC-MS analysis of authentic standards of Rd, Rg3, Rh2
and protopanaxadiol. Moreover, the LC-MS-MS analysis
indicated that these deglycosylated metabolites were sub-
sequently oxygenated in digestive tracts. Thus, deglycosy-
lation and subsequent oxygenation are the major
metabolic pathways of orally administered Rb1 in rats.
Figure 1 illustrates the proposed metabolic pathways of
Rb1.
Metabolites of Rg3 in rat feces
Six metabolites were detected in rat feces samples col-
lected 0-24 hours after Rg3 was orally administered. The
same LC-MS and MS-MS method as for Rb1 was used to
detect major deglucosylated and further oxygenated
metabolites of Rg3. The MS-MS results were similar to
those for Rb1. Rh2 and protopanaxadiol as the deglucosy-
lated products were also confirmed by reference stan-
dards. Figure 4 summarizes the major metabolites of Rg3
detected in the rat feces samples and the metabolic path-
way in rat gastrointestinal tracts. After the oral adminis-
Figure 5 Metabolic pathways of Rh2 orally administered to rats.
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tration, oxygenation and deglycosylation appeared to be
the major metabolic pathways of ginsenosides. Metabo-
lites were detected for the parent Rg3 and its deglucosy-
lated metabolites including the mono- and deoxygenated
products of protopanaxadiol.
Metabolites of Rh2 in rat feces
Three major metabolites were detected in rat feces sam-
ples collected 0-48 hours after Rh2 was orally adminis-
tered. The LC-MS and MS-MS method in positive ESI
mode was used to detect and confirm the metabolites
respectively. Oxygenated products, such as mono-oxy-
genated protopanaxadiol, were also identified. Deglycosy-
lation and oxygenation were the major metabolic
pathways of Rh2. Figure 5 illustrates the proposed meta-
bolic pathway of Rh2 in rat gastrointestinal tracts.
Conclusion
Oxygenation and deglycosylation are two major meta-
bolic pathways of the ginsenosides in rat gastrointestinal
tracts. Furthermore, Rh2 is a metabolite of Rb1 and Rg3,
whereas Rg3 i s  a  m e t a b o l i t e  o f  R b 1. Some metabolites
such as protopanaxadiol and monooxygenated protopa-
naxadiol are metabolites of all three ginsenosides.
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